Fresenius stock holds near EUR 46.36 after stake sale
Published on 08/25/2026 at 17:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Fresenius SE & Co. KGaA (DE0005785604) stock traded at EUR 46.36 on August 21, 2026, after the company pointed investors to a EUR 300 million cash inflow from the sale of part of its Fresenius Medical Care stake.
The latest transaction disclosure dated August 24, 2026 says Fresenius agreed on August 20, 2026 to sell 7,800,000 Fresenius Medical Care shares at EUR 39.56 each, implying gross proceeds of just under EUR 309 million and setting a new valuation marker for the group.
The same reporting window also puts Fresenius Medical Care stock at EUR 40.30 on August 24, 2026, which is EUR 1.84 above the EUR 38.46 placement price cited in transaction commentary and shows that the market has kept the deal within a tight trading band.
Stake sale sets the tone
The block trade is the main catalyst because it turns a strategic holding into immediate cash while leaving Fresenius with a substantial stake in the dialysis company. The documentation says the transaction was expected to close on August 25, 2026, and that the parent would still remain above one quarter of the outstanding shares.
For investors, the numbers matter more than the headline. EUR 300 million in proceeds, 7,800,000 shares sold, and EUR 39.56 per share give the market a concrete frame for judging how much balance sheet flexibility the transaction may add.
What the price shows
Per recent market data for the Vienna Stock Exchange, Fresenius stock rose 0.46 percent on August 21, 2026 and gained 13.05 percent versus July 23, 2026, while closing at EUR 46.36. That combination puts the shares well above the stake-sale pricing reference and suggests investors have not treated the block trade as a sign of distress.
The trading range around the transaction is also tight enough to matter. Fresenius Medical Care closed at EUR 40.30 on August 24, 2026, only EUR 1.84 above the EUR 38.46 benchmark in the placement commentary, a spread of 4.8 percent.
Dialysis remains the core
Fresenius Medical Care remains the group’s most important strategic asset because dialysis still sits at the center of the company’s healthcare model. The dialysis business combines clinic operations, patient treatments, and medical equipment, which gives Fresenius recurring exposure to reimbursement trends and patient volumes.
That structure is why the stake sale matters beyond the cash amount. A partial monetization of a core holding can lift liquidity, but it also keeps the market focused on how much strategic influence Fresenius wants to retain in the dialysis segment.
Representative product
A representative Fresenius product area is dialysis care and related equipment through Fresenius Medical Care. The segment includes hemodialysis treatments, dialysis machines, dialyzers, and consumables used in clinics and treatment centers worldwide.
That mix of services and devices is central to the company’s recurring revenue profile and helps explain why ownership changes in the dialysis unit attract close investor attention.
Fresenius shares stay steady
As of August 21, 2026, Fresenius stock remained at EUR 46.36 on the Vienna Stock Exchange. The level gives investors a simple reference point as they weigh the EUR 300 million stake sale against the group’s broader healthcare footprint.
Fact box
Company: Fresenius SE & Co. KGaA
ISIN: DE0005785604
Ticker: FRE
Exchange: Vienna Stock Exchange
Price (as of August 21, 2026, 4:00 p.m. ET): EUR 46.36
Sector / Industry: Healthcare / Healthcare services
